MEDICINA
Departamento
KU Leuven
Lovaina, BélgicaPublicaciones en colaboración con investigadores/as de KU Leuven (73)
2024
-
Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
Advances in Therapy, Vol. 41, Núm. 2, pp. 696-715
-
Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022
eClinicalMedicine, Vol. 71
-
Endothelial Activation and Stress Index (EASIX) to predict mortality after allogeneic stem cell transplantation: A prospective study
Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 1
-
Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study
Clinical Lymphoma, Myeloma and Leukemia, Vol. 24, Núm. 3, pp. 194-202
-
Upper and/or Lower Respiratory Tract Infection Caused by Human Metapneumovirus After Allogeneic Hematopoietic Stem Cell Transplantation
Journal of Infectious Diseases, Vol. 229, Núm. 1, pp. 83-94
2023
-
Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma
Advances in Therapy, Vol. 40, Núm. 5, pp. 2412-2425
-
Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
Blood Advances, Vol. 7, Núm. 11, pp. 2645-2655
-
Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study
HemaSphere, Vol. 7, Núm. 9, pp. E942
-
Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma
Blood Advances, Vol. 7, Núm. 22, pp. 7141-7150
-
Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma
Future Oncology, Vol. 19, Núm. 12, pp. 811-818
-
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
The Lancet Oncology, Vol. 24, Núm. 6, pp. e255-e269
-
Severe cytopenia after CD19 CAR T-cell therapy: A retrospective study from the EBMT Transplant Complications Working Party
Journal for ImmunoTherapy of Cancer, Vol. 11, Núm. 4
2022
-
COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP
Blood Advances, Vol. 6, Núm. 7, pp. 2427-2433
-
Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT
Blood Cancer Journal, Vol. 12, Núm. 9
-
Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up': [Ann Oncol 2021; 32(3): 309-322
Annals of oncology : official journal of the European Society for Medical Oncology
-
Corrigendum: “Corrigendum to ‘Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’”: (Annals of Oncology (2022) 33(1) (117), (S0923753421044999), (10.1016/j.annonc.2021.10.001))
Annals of Oncology
-
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma
Leukemia, Vol. 36, Núm. 5, pp. 1371-1376
-
Teclistamab in Relapsed or Refractory Multiple Myeloma
New England Journal of Medicine, Vol. 387, Núm. 6, pp. 495-505
-
The Euroflow PID Orientation Tube in the diagnostic workup of primary immunodeficiency: Daily practice performance in a tertiary university hospital
Frontiers in Immunology, Vol. 13
-
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
Blood, Vol. 140, Núm. 11, pp. 1229-1253